[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Moens Maarten\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100459945","return-to-work-for-persistent-spinal-pain-syndrome-type-ii-patients-100459945",false,"NCT05269212","Return to Work for Persistent Spinal Pain Syndrome Type II Patients","Objectifying Performance Assessments and Personalized Rehabilitation Trajectories to Improve Return to Work in Patients With Persistent Spinal Pain Syndrome Type II: a Randomized Controlled Trial.","OPERA","Inclusion Criteria:\n\n* Persistent Spinal Pain Syndrome Type II (PSPS-T2)\n* Chronic pain as a result of PSPS-T2 that exists for at least 6 months with a pain intensity of at least 4\u002F10 on the Numeric Rating Scale, refractory to conservative treatment.\n* Dutch speaking persons\n* Patient has been informed of the study procedures and has given written informed consent\n* Patient willing to comply with study protocol including attending the study visits\n\nExclusion Criteria:\n\n* Suffering from another chronic illness characterised by chronic generalized widespread pain (e.g. rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome, scleroderma).\n* Pregnancy","ALL","18 Years","60 Years",{"count":21,"type":22},112,"ESTIMATED","INTERVENTIONAL",[25],"NA","A multicenter randomized controlled trial will be conducted to evaluate whether the ability to work in Persistent Spinal Pain Syndrome Type II (PSPS-T2) patients after SCS implantation is different after a personalized biopsychosocial rehabilitation program specifically targeting return to work (RTW) compared with usual care.",[28,29],"Failed Back Surgery Syndrome","Spinal Cord Stimulation","RECRUITING","2025-10-01",{"date":33,"type":34},"2025-10-02","ACTUAL",{"date":36,"type":34},"2022-05-10",{"date":38,"type":22},"2027-08",{"name":40,"class":41},"Moens Maarten","OTHER",5,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100444483","differential-target-multiplexed-spinal-cord-stimulation-100444483","NCT05068011","Differential Target Multiplexed Spinal Cord Stimulation","Differential Target Multiplexed Spinal Cord Stimulation: a Multicenter Cohort Study","DETECT","Inclusion Criteria:\n\n* Patients with severe chronic pain (\\> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician\n* Age \\> 18 years\n* Patient has been informed of the study procedures and has given written informed consent\n* Patient willing to comply with study protocol including attending the study visits\n\nExclusion Criteria:\n\n* Expected inability of the patient to receive or properly operate the spinal cord stimulation system\n* History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew\n* Active malignancy\n* Addiction to drugs, alcohol (\\>5 units per day) and\u002For medication\n* Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and\u002For ability to evaluate treatment outcome as determined by investigator\n* Immune deficiency (e.g. HIV positive, immunosuppressive treatment)\n* Life expectancy \\\u003C 1 year\n* Local infection or any other skin disorder at site of incision\n* Pregnancy\n* Other implanted active medical device",{"count":52,"type":22},250,"OBSERVATIONAL","Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle\u002Fsurgical leads versus percutaneous leads.",[28,56],"Persistent Spinal Pain Syndrome Type 2",[58],"differential target multiplexed spinal cord stimulation","2024-08-15",{"date":61,"type":34},"2024-08-16",{"date":63,"type":34},"2021-10-06",{"date":65,"type":22},"2026-08",{"name":40,"class":41},14,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":5},"100505455","pain-medication-tapering-for-patients-with-persistent-spinal-pain-syndrome-type-2-treated-with-spinal-cord-stimulation-100505455","NCT05861609","Pain Medication Tapering for Patients With Persistent Spinal Pain Syndrome Type 2, Treated With Spinal Cord Stimulation.","PIANISSIMO","Inclusion Criteria:\n\n* Patients with PSPS T2, defined as patients suffering from neuropathic pain of radicular origin with pain in the lower back and\u002For leg(s), of an intensity of at least 4\u002F10 on the Numeric Rating Scale, for a period of at least 6 months after a minimum of one anatomically successful spinal surgery and being refractory to conservative treatment (according to Belgian reimbursement rules from January 1st, 2018)\n* Patients need to be scheduled for SCS to be eligible for participation in the study\n* Currently taking opioids\n* 18 years and older\n* Speaking and reading Dutch or French\n\nExclusion Criteria:\n\n* Being actively treated for cancer.\n* Having a life expectancy below 6 months.\n* Receiving intrathecal drug delivery.\n* Patients with contraindications for Clonidine (e.g., known hypotension which requires medication) or for Buprenorphine\u002FNaloxone (e.g., severe respiratory insufficiency, hepatic insufficiency).\n* Epilepsy treated by Pregabalin.\n* Currently using benzodiazepines at more than 40 mg diazepam-equivalents per day.",{"count":76,"type":22},195,[25],"The primary objective of the study is to examine whether there is a difference in disability after 12 months of Spinal Cord Stimulation (SCS) in patients with Persistent Spinal Pain Syndrome Type 2 (PSPS T2) after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation. The secondary objective of the study is to examine whether there is a difference after 12 months of SCS in PSPS T2 patients after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation on pain intensity, health-related quality of life, participation, domains affected by substance use, anxiety and depression, medication use, psychological constructs, sleep, central sensitization, and healthcare expenditure.",[56,29],"2023-10-17",{"date":82,"type":34},"2023-10-18",{"date":84,"type":34},"2023-09-29",{"date":86,"type":22},"2026-09",{"name":40,"class":41},""]